8-K: Avalo Therapeutics Reports 2025 Results, Q2 2026 Trial Data Expected

Avalo Therapeutics announced its 2025 financial results and anticipates topline data from its Phase 2 LOTUS trial for abdakibart in Q2 2026.

Summary

• Reported 2025 financial results and business updates, highlighting disciplined execution focused on the LOTUS trial.
• Topline data from the Phase 2 LOTUS trial of abdakibart (AVTX-009) for the treatment of hidradenitis suppurativa is expected in the second quarter of 2026.
• Cash, cash equivalents, and short-term investments totaled approximately $98.3 million as of December 31, 2025.
• Current cash position is expected to provide a runway into 2028.
• Net loss for the year ended December 31, 2025, was $78.3 million, an increase from $35.1 million in 2024.
• Research and development expenses increased by $25.6 million to $50.1 million in 2025, primarily driven by costs related to the Phase 2 LOTUS trial.
• General and administrative expenses increased by $5.7 million to $22.9 million in 2025, primarily due to stock-based compensation expense and headcount additions.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a mixed update. While the cash runway into 2028 is positive, the significant increase in net loss and operating expenses, despite an improved per-share loss due to dilution, indicates a high burn rate ahead of critical Phase 2 data, which carries inherent clinical trial risk.

Positives

• Cash, cash equivalents, and short-term investments of $98.3 million as of December 31, 2025, are expected to fund operations into 2028.
• Approaching a transformational milestone with topline data from the Phase 2 LOTUS trial of abdakibart (AVTX-009) expected in Q2 2026.
• Abdakibart (AVTX-009) is a high-affinity IL-1 inhibitor targeting a large unmet need in hidradenitis suppurativa.
• Basic net loss per share improved to $5.84 in 2025 from $7.94 in 2024, and diluted net loss per share improved to $5.84 from $20.91 in 2024, despite a higher net loss, due to increased weighted average shares outstanding.

Negatives

• Net loss significantly increased to $78.3 million for the year ended December 31, 2025, from $35.1 million for the year ended December 31, 2024.
• Research and development expenses rose by $25.6 million to $50.1 million in 2025, indicating a higher burn rate for clinical trials.
• General and administrative expenses increased by $5.7 million to $22.9 million in 2025.
• Net cash used in operating activities was $51.5 million for the year ended December 31, 2025.
• Total assets decreased from $150,732 thousand in 2024 to $116,458 thousand in 2025.

Risks

• Changes in domestic and foreign business, market, financial, political, and legal conditions.
• Drug development costs, timing of trials, and trial results.
• Reliance on investigators and enrollment of patients in clinical trials.
• Reliance on key personnel.
• Regulatory risks.
• General economic and market risks and uncertainties.
• Other risks detailed in Avalo's filings with the Securities and Exchange Commission.

Future Outlook

Avalo Therapeutics expects topline data from its Phase 2 LOTUS trial of abdakibart (AVTX-009) for hidradenitis suppurativa in the second quarter of 2026. The company anticipates its current cash, cash equivalents, and short-term investments will fund operations into 2028.

Management Comments

• "2025 was a year of disciplined execution focused on the LOTUS trial, and we are thrilled to be approaching a transformational milestone with our topline data release expected in the second quarter of 2026." Dr. Garry Neil, Chief Executive Officer.
• "We look forward to sharing the results which have the potential to demonstrate abdakibart’s (AVTX-009) high affinity inhibition of IL-1 and positive impact on addressing the large unmet need of patients living with hidradenitis suppurativa." Dr. Garry Neil, Chief Executive Officer.

Industry Context

StockSavvy.ai notes that Avalo Therapeutics operates in the highly competitive and capital-intensive clinical-stage biotechnology sector, specifically focusing on IL-1-based treatments for immune-mediated inflammatory diseases. The focus on hidradenitis suppurativa (HS) addresses a significant unmet medical need, with HS affecting an estimated 0.7-1.2% of the U.S. population. Success in the Phase 2 LOTUS trial could position abdakibart as a key player in a market with limited effective treatments, potentially competing with existing biologics or other pipeline candidates targeting inflammatory pathways.

Comparison to Industry Standards

• NA

Stakeholder Impact

• Shareholders: Potential for significant value creation or loss depending on the outcome of the Phase 2 LOTUS trial. Increased net loss and R&D expenses indicate continued investment in the pipeline, which is typical for a clinical-stage biotech, but also a higher burn rate. The improved EPS is due to dilution, which is not a positive for existing shareholders.
• Patients (with HS): The ongoing Phase 2 LOTUS trial offers hope for a new, effective treatment for a debilitating condition with significant unmet needs.
• Employees: Continued employment and potential growth opportunities if the clinical trials are successful. Increased G&A expenses due to headcount additions suggest some growth.
• Creditors/Suppliers: The cash runway into 2028 provides assurance of the company's ability to meet its short-to-medium term obligations.

Next Steps

• Release topline data from the Phase 2 LOTUS trial of abdakibart (AVTX-009) in the second quarter of 2026.
• Continue to develop IL-1-based treatments for immune-mediated inflammatory diseases.
• Explore additional opportunities in prevalent indications with significant unmet needs.

Key Dates

Recommendation

The company's financial position, with a cash runway into 2028, provides stability. However, the significant increase in net loss and R&D expenses reflects a high burn rate typical of clinical-stage biotechs. The upcoming Phase 2 LOTUS trial data in Q2 2026 represents a major catalyst. Given the binary nature of clinical trial results, a "hold" recommendation is appropriate for seasoned investors awaiting this critical data, as the stock's future performance will largely hinge on these results. A "buy" would be too speculative given the risks, and a "sell" would be premature before the data readout, especially with a decent cash position.

Keywords

Avalo Therapeutics, AVTX, Financial Results, 2025 Earnings, Biotechnology, Clinical Stage, Abdakibart, AVTX-009, Hidradenitis Suppurativa, HS, Phase 2 LOTUS trial, IL-1 inhibitor, Inflammatory Diseases, Clinical Data, Cash Runway